Cargando…

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan-Rong, Liu, Chi-Hung, Sun, Wei-Chiao, Fan, Pei-Yi, Liu, Feng-Hsuan, Chen, Tien-Hsing, Wu, Victor Chien-Chia, Lin, Chihung, Hsiao, Ching-Chung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/ https://www.ncbi.nlm.nih.gov/pubmed/34575605 http://dx.doi.org/10.3390/jpm11090828

Ejemplares similares

Temporal trends of incident diabetes mellitus and subsequent outcomes in patients receiving kidney transplantation: a national cohort study in Taiwan
por: Yeh, Hsuan, et al.
Publicado: (2020)

Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
por: Tseng, Chin-Hsiao
Publicado: (2012)

Blocking of SGLT2 to Eliminate NADPH-Induced Oxidative Stress in Lenses of Animals with Fructose-Induced Diabetes Mellitus
por: Chen, Ying-Ying, et al.
Publicado: (2022)

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis
por: Tseng, Chin-Hsiao
Publicado: (2018)

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
por: Tseng, Chin-Hsiao
Publicado: (2022)

Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
por: Chen, Ying-Ying, et al.
Publicado: (2019)

Pioglitazone, bladder cancer, and detection bias
por: Dolin, Paul
Publicado: (2014)

Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
por: Tseng, Chin-Hsiao
Publicado: (2022)

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
por: Tahara, Atsuo, et al.
Publicado: (2019)

Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
por: Tseng, Chin-Hsiao
Publicado: (2022)

Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases
por: Hsiao, Ching-Chung, et al.
Publicado: (2022)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

The Association of Pioglitazone and Urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease
por: Lee, Mei-Yueh, et al.
Publicado: (2014)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Pioglitazone and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2014)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Incidence of Bladder Cancer in Type 2 Diabetes Mellitus Patients: A Population-Based Cohort Study
por: Pan, Yueh, et al.
Publicado: (2020)

SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
por: Park, Jong Suk, et al.
Publicado: (2011)

The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus
por: Mori, Hiroko, et al.
Publicado: (2017)

Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
por: Yang, Shao-ling, et al.
Publicado: (2018)

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
por: Filipova, Elena, et al.
Publicado: (2017)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
por: Kaur, Simran, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
por: Tsai, Wen-Hsuan, et al.
Publicado: (2021)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
por: Pitt, Bertram, et al.
Publicado: (2021)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2021)

Pioglitazone alters fat distribution in patients with type 2 diabetes mellitus, in contrast to metformin
por: Jonker, Jacqueline T, et al.
Publicado: (2009)

The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
por: Song, Sun Ok, et al.
Publicado: (2012)

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
por: Gupta, Sunil, et al.
Publicado: (2015)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2012)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_85fh9fj0obbb2lgm5sbpt956eq